Travelan® Phase 2 Study Results Published Melbourne, Australia, October 13, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports. A copy of the...